AssayIndex
KP cross-section

KP by compound

KP records split by compound, with the index-wide comparison for the same compound beside each one. 24 compounds, 223 records. Cells below n=3 print their raw values instead of a median.

24 compounds223 records
CompoundClassReportsKP median %Index median %Δ (pp)SpecPass %
TirzepatideIncretin4098.1098.55-0.4597.0100
SemaglutideIncretin2998.3198.89-0.5897.0100
BPC-157Tissue-repair1698.5399.16-0.6398.0100
RetatrutideIncretin1496.6998.37-1.6896.564
DesmopressinHypothalamic1298.6698.83-0.1798.567
SemaxNeuroactive1298.9599.46-0.5198.583
5-Amino-1MQNon-peptide1199.5899.45+0.1398.0100
Melanotan IIMelanocortin-receptor998.0999.42-1.3398.50
IpamorelinGrowth-hormone899.1499.47-0.3399.075
SermorelinGrowth-hormone898.8099.06-0.2698.0100
TB-500Tissue-repair7 n=799.2999.53-0.2498.5100
ExenatideIncretin7 n=798.1898.98-0.8098.071
KPVTissue-repair7 n=799.1699.64-0.4899.071
IGF-1 LR3Growth-hormone7 n=798.0798.28-0.2195.0100
HexarelinGrowth-hormone6 n=698.6999.59-0.9099.017
EpitalonShort6 n=698.5899.56-0.9899.033
CJC-1295 (no DAC)Growth-hormone5 n=599.1499.09+0.0598.0100
N-Acetyl Semax AmideNeuroactive4 n=498.6499.35-0.7198.550
GHRP-6Growth-hormone4 n=498.4999.54-1.0599.00
LiraglutideIncretin3 n=399.6299.00+0.6397.5100
MK-677 (Ibutamoren mesylate)Non-peptide3 n=399.5299.49+0.0398.5100
CJC-1295 with DACGrowth-hormone2 n=2n<398.9597.5100
SelankNeuroactive2 n=2n<399.5999.00
PemvidutideIncretin1 n=1n<398.2596.0100
95.596.397.197.998.799.5100.3TirzepatideTirzepatide: Q1 97.65, median 98.10, Q3 98.50, n=40outlier 99.93n=40SemaglutideSemaglutide: Q1 98.02, median 98.31, Q3 98.55, n=29outlier 99.77outlier 99.83outlier 99.85outlier 99.93outlier 99.93outlier 99.93n=29BPC-157BPC-157: Q1 98.39, median 98.53, Q3 98.65, n=16n=16RetatrutideRetatrutide: Q1 96.47, median 96.69, Q3 98.19, n=14n=14DesmopressinDesmopressin: Q1 98.45, median 98.66, Q3 98.72, n=12n=12SemaxSemax: Q1 98.73, median 98.95, Q3 99.18, n=12n=125-Amino-1MQ5-Amino-1MQ: Q1 99.46, median 99.58, Q3 99.68, n=11n=11Melanotan IIMelanotan II: Q1 97.96, median 98.09, Q3 98.16, n=9n=9IpamorelinIpamorelin: Q1 98.93, median 99.14, Q3 99.28, n=8n=8SermorelinSermorelin: Q1 98.38, median 98.80, Q3 99.13, n=8n=8TB-500TB-500: Q1 99.19, median 99.29, Q3 99.47, n=7n=7ExenatideExenatide: Q1 98.03, median 98.18, Q3 98.46, n=7n=7KPVKPV: Q1 99.00, median 99.16, Q3 99.22, n=7n=7IGF-1 LR3IGF-1 LR3: Q1 97.70, median 98.07, Q3 98.16, n=7outlier 96.98n=7 Purity (% area)
Figure. Distribution per compound where n ≥ 4. Rows are ordered by coverage, not by result.

Which of these lines KP actually stocks

Coverage here reflects what has been submitted to the index, not what is on the catalogue. Zhuhai Kerui Biotechnology Co., Ltd. lists considerably more than the 24 compounds above. Of those 24, 16 have been seen arriving from a domestic warehouse rather than as a cross-border consignment — that is the whole of what the index can say about which lines are held in regional stock, and it is a record of what was submitted, not a stock position. The catalogue and the current stock position are on the supplier's own site.

Browse the KP catalogue at keruipeptides.com →